| Outcome Measures: |
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE), Treatment-emergent AEs (TEAEs) are defined as any AE that started on or after the first dose of study medication through 30 days following the last dose., At the Primary Analysis (when all the patients have completed their Day 150 visit)|Number of Participants and Severity of Local i.v.-Site Reactions,, Number of Participants and severity of local intravenous site reactions after receiving the three doses are reported., 5 months post first dose|Changes From Baseline of Creatinine, Safety/tolerability outcomes - creatinine, 5 months post first dose|Changes From Baseline of Aspartate Aminotransferase, Safety/tolerability outcomes - Aspartate Aminotransferase, 5 months post first dose|Changes From Baseline of Alanine Aminotransferase, Safety/tolerability outcomes - Alanine Aminotransferase, 5 months post first dose|Changes From Baseline of Total Bilirubin, Safety/tolerability outcomes - Total Bilirubin, 5 months post first dose | Secondary: Assessment of the HLA-E-restricted CD8+ T Cell Regulatory Activity ("Potency Assay"), CD8+ T cell Inhibition Assay is used to determine whether AVT001 corrects the defect of the dysfunctional Q/E CD8+ Treg pathway in T1D patients. More specifically, this assay detects the specific recognition between the TCR on patients' Q/E CD8+Treg cells and the "common target structure", the HLA-E/Hsp60sp complex, expressed on the surface of the artificially established target cells. The % inhibition measures the function of down-regulation by Q/E CD8+ Tregs via comparing the % of inhibition of TH1 cells versus TB1 cells. By assessing the % inhibition of the TH1 cells of the patient's CD8+ T cells, the CD8+ T cell Inhibition Assay detects the specific recognition of the common target structure (HLA-E/Hsp60sp) on TH1 cells by the TCR on the patient's T cells to be tested. A negative value means the measured Q/E CD8+ Tregs completely lose its inhibition function, and the TH1 cells cultured with it happened to grow faster than the corresponding TB1 cells as its control., 5 months post first dose|Changes From Baseline in the Area Under the Curve (AUC) of the Stimulated C-peptide Levels Over a 4-hour Mixed Meal Tolerance Test (MMTT), The area under the stimulated C-peptide curve (AUC) over the first 4-hour period of a mixed meal glucose tolerance test is calculated using the trapezoidal rule that is a weighted sum of the C-peptide values over the 240 minutes. The AUC is normalized by dividing it with 240 mins, therefore, its unit is nmol/L. Missing C-peptide levels at any given timepoint is not imputed. In the calculation of the AUC when C-peptide levels are missing, a line is drawn from the last timepoint with a non-missing C-peptide to the next timepoint with non-missing C-peptide., 5 months post first dose|Changes From Baseline in HbA1c, HbA1c is a blood test that is used to monitor blood glucose control in people with diabetes. HbA1c is short for glycated haemoglobin. The test is also sometimes called haemoglobin A1c., 5 months post first dose
|
